Dioscuri Biopharmaceuticals

What Dioscuri Biopharmaceuticals does

Dioscuri Biopharmaceuticals GmbH is a privately held, pre-clinical biotechnology company founded in 2017 and headquartered in Munich, Germany. The company is focused exclusively on developing treatments for Acute Myeloid Leukemia (AML), with a stated mission to eliminate chemotherapy-resistant leukemic stem cells and stem-like progenitors that drive disease relapse. Its single technology platform centers on 3rd-generation conditional bispecific T-cell engagers engineered with built-in checkpoint inhibition, designed to overcome the immune evasion mechanisms specific to leukemic stem cells.

The company has not yet publicly disclosed named product candidates, clinical trial activity, partnership deals, or funding rounds; both the Programs and Science sections of the corporate website are currently marked 'COMING SOON'. Leadership consists of Managing Director and Co-Founder Marc Lohrmann, and headcount is reported in the 11-50 range, consistent with a sub-scale, discovery-stage biotech. Operating geographies are listed as Europe, and the legal entity is registered in Germany as a private limited company (HRB 296825, Amtsgericht München).

As a pre-revenue biopharmaceutical, Dioscuri's business model is contingent on future commercialization through pharmaceutical product sales or licensing following regulatory approval. There are no disclosed pricing structures, distribution channels, marketing channels, awards, certifications, patents, or third-party partnerships in the available inputs, leaving the commercial pathway undefined at present.

Name

Dioscuri Biopharmaceuticals

Legal name

Dioscuri Biopharmaceuticals GmbH

Website

https://dioscuri.bio

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Dioscuri Biopharmaceuticals is a pre-clinical Munich-based biotech developing 3rd-generation conditional bispecific T-cell engagers with built-in checkpoint inhibition to eliminate chemotherapy-resistant leukemic stem cells in Acute Myeloid Leukemia patients.

Ownership category

akta.pro rank

Product category

Acute Myeloid Leukemia Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAAAB

Recombinant Protein Therapeutics (enzymes, hormones, growth factors)

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

• Acute myeloid leukemia treatment
• Bispecific T-cell engagers
• Leukemic stem cell targeting
• Cancer immunotherapy
• Bispecific antibody therapeutics

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Revenue: As a biopharmaceutical company developing novel cancer therapeutics, revenue would be generated through the sale of approved drugs upon successful clinical development and regulatory approval.

Core offering

Dioscuri Biopharmaceuticals is a pre-clinical biopharmaceutical company developing third-generation conditional bispecific T-cell engagers with built-in checkpoint inhibition, engineered to target and eliminate chemotherapy-resistant and relapse-driving leukemic stem cells and stem-like progenitors in Acute Myeloid Leukemia (AML) patients. The company is headquartered in Munich, Germany, and individual drug programs are not yet publicly disclosed, with the website's Programs page marked "COMING SOON."

Product overview

Dioscuri Biopharmaceuticals is a biopharmaceutical company developing a single therapeutic technology platform focused on 3rd-generation conditional bispecific T-cell engagers with built-in checkpoint inhibition, engineered to target and eliminate chemotherapy-resistant and relapse-driving leukemic stem cells in Acute Myeloid Leukemia (AML) patients. The programs are currently in development with the Programs page indicating 'COMING SOON' — no individual product names or modules are yet publicly disclosed.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Genmab: Genmab's DuoBody bispecific platform has produced approved and clinical-stage hematology assets (including Janssen-partnered programs), making it a broad incumbent in the engineered antibody space relevant to Dioscuri's modality.
• Amgen: Amgen pioneered the BiTE platform, including Blincyto for B-ALL, and continues to advance next-generation T-cell engagers in hematology—the dominant incumbency reference point and pre-existing IP landscape for any new BiTE/conditional BiTE entrant.
• Zymeworks: Zymeworks commercializes Azymetric and other bispecific antibody platforms and is increasingly focused on engineered heme and solid tumor programs—an incumbent platform peer for any next-generation bispecific developer.
• MacroGenics: MacroGenics operates multiple bispecific antibody platforms (DART, TRIDENT) with clinical-stage heme programs, making it an established incumbent in the same bispecific T-cell engager space Dioscuri targets.

Emerging players

• Adagene: Adagene uses AI-guided antibody engineering to develop conditionally active bispecifics and ADCs in oncology, including in hematologic malignancies—a comparable emerging player focused on conditional bispecific antibody architectures.
• Aprea Therapeutics: Aprea is a small biotech developing therapies (including p53-reactivation approaches) targeting AML biology and chemo-resistance—an indication-overlapping emerging peer rather than a direct modality competitor.

Direct peers

• Immune-Onc Therapeutics: Immune-Onc develops first-in-class bispecific antibodies targeting myeloid checkpoints and immune evasion in hematologic malignancies—comparable as a small preclinical bispecific biotech addressing immune evasion mechanisms in leukemia.
• Maverick Therapeutics: Maverick built the COBRA platform for conditionally active bispecific T-cell engagers targeting solid and hematologic tumors and was acquired by Takeda—comparable as a conditional bispecific T-cell engager platform developer with similar mechanistic goals to Dioscuri's 'conditional' architecture.
• Cullinan Oncology: Cullinan Oncology develops CLN-049, an FLT3×CD3 bispecific T-cell engager for AML—the closest possible comparable to Dioscuri's leukemic stem cell T-cell engager program, making it the most directly relevant peer.
• Harpoon Therapeutics: Harpoon developed proprietary T-cell engagers for hematologic malignancies including leukemia and was acquired by Merck for its tri-specific T-cell engager platform—directly comparable as a small-cap bispecific T-cell engager biotech focused on heme oncology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dioscuri Biopharmaceuticals